Acura Targets 4 Rivals Over Generic Oxecta Plans

Law360, New York (November 1, 2012, 5:22 PM EDT) -- Acura Pharmaceuticals Inc. hit four rivals with patent infringement suits in Delaware federal court Wednesday, seeking to block their plans to market generic versions of opioid painkiller Oxecta.

According to the suits, which target Impax Laboratories Inc., Par Pharmaceutical Inc., Sandoz Inc. and several units of Watson Laboratories Inc., the companies’ abbreviated new drug applications for 5- and 7.5-milligram dosage strength versions of generic oxycodone hydrochloride infringe a patent for Oxecta, an abuse-resistant version of the opioid painkiller.

“Acura will be substantially and irreparably harmed by...
To view the full article, register now.